Clover Bio Dumps GSK Adjuvant Technology, Will Take Dynavax to Vaccine Dance | BioSpace
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover, Dynavax begin COVID-19 vaccine late-stage trials
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover Biopharmaceuticals | Science | Trimer-Tag™
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials - The Lancet Infectious Diseases
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
Clover Biopharmaceuticals | Science | The Trimer-Tag™ Technology Platform
Clover Biopharmaceuticals | Science | Trimer-Tag™
Clover Biopharmaceuticals | Science | Trimer-Tag™
PharmaBoardroom - China's Clover Biopharmaceuticals Partners with GSK on COVID-19 Vaccine
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications